Skip to content

A study to compare the effect of Homoeopathic Individualized medicines and Viburnum Opulus 6X for pain management of Primary dysmenorrhea in Adolescent girls

A comparitive study on the effectiveness of individualized homoeopathic medicines versus viburnum opulus 6x for pain management in adolescent girls with primary dysmenorrhea - nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/10/074849
Enrollment
80
Registered
2024-10-07
Start date
Unknown
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N944- Primary dysmenorrhea

Interventions

Intervention1: individualized homoeopathic medicine: in globules in suitable potency is given orally for 6 months based on the susceptibility of the participant Control Intervention1: viburnum opulus

Sponsors

White Memorial Homoeo Medical College and Hospita
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Females of age 10 to 17 years Patients with symptoms of primary dysmenorrhea with WaLIDD score between 1 to 7 Patients with informed patient and parent Consent.

Exclusion criteria

Exclusion criteria: Patients with other systemic diseases. Patients who are using other pain relieving medications Patients undergoing treatment for any other chronic diseases. Patients with secondary dysmenorrhea Patients with WaLIDD Score more than 8 (severe)

Design outcomes

Primary

MeasureTime frame
TO COMPARE SYMPTOM SEVERITY BASED ON PRE AND POST TREATMENT CHANGE IN WALIDD SCORE Timepoint: 1 YEAR

Secondary

MeasureTime frame
TO FIND THE MOST COMMON INDICATED INDIVIDUALIZED HOMOEOPATHIC MEDICINE PRESCRIBED IN THE STUDYTimepoint: 1 YEAR

Countries

India

Contacts

Public ContactDr.Juhi Ninan

White Memorial Homoeo Medical College and Hospital

Judzon3535@gmail.com9538484284

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026